Linux fréttir

Ad giant just confirmed its cloudy arm will embrace security shop in $30B deal

Wiz security researchers think they've found the root cause of the GitHub supply chain attack that unfolded over the weekend, and they say that a separate attack may have been to blame.…

Dispute over app privacy escalates into legal brawl

Phyllis Jager, CEO of New York-based creative agency zuMedia, has perhaps, like some of you, privacy concerns about the pictures DoorDash drivers take to prove they've correctly made their deliveries.…

There's nothing bog-standard about this bombshell loo-suit

Rival HR technology unicorns are at each other's throats in a courtroom brawl over alleged corporate espionage.…

Google parent Alphabet has agreed to buy cyber security start-up Wiz for $32 billion, the biggest acquisition in the search group's history, according to Financial Times, which cites sources. From the report: Alphabet held talks over a $23 billion acquisition of Wiz last year, although the negotiations collapsed after some of the cyber security company's directors and investors became worried about antitrust hurdles. The deal, which will rank as the biggest deal of the year so far, will be announced on Tuesday morning, a person said. It will probably still face scrutiny from the Federal Trade Commission under President Donald Trump, whose new chair Andrew Ferguson has maintained guidelines giving the agency the ability to block large deals used by his predecessor Lina Khan.

Read more of this story at Slashdot.

Govt wants to learning mistakes of serially breached record holders so it can, er, liberalize data sharing regs under new law

The UK government is inviting experts to provide insights about the data brokerage industry and the potential risks it poses to national security as it moves to push new data-sharing legislation over the line.…

HR software startup Rippling has sued competitor Deel, alleging that Deel orchestrated corporate espionage by recruiting an employee within Rippling to steal trade secrets, including customer data, sales strategies, and internal records. The lawsuit (PDF) claims the spy shared confidential information with Deel executives and a reporter, leading to legal action under the Racketeer Influenced and Corrupt Organizations (RICO) Act. Deel denies wrongdoing and plans to counter the claims. CNBC reports: The two startups are among the most world's most valuable. Investors valued Rippling at $13.5 billion in a funding round announced last year, while Deel told media outlets in 2023 that it was worth $12 billion. Deel ranked No. 28 on CNBC's 2024 Disruptor 50 list. "Weeks after Rippling is accused of violating sanctions law in Russia and seeding falsehoods about Deel, Rippling is trying to shift the narrative with these sensationalized claims," a Deel spokesperson told CNBC in an email. "We deny all legal wrongdoing and look forward to asserting our counterclaims." Rippling confirmed its findings earlier this month. The company's general counsel sent a letter to three Deel executives that referred to a new Slack channel, and the Deel spy quickly looked for it. Rippling subsequently served a court order to the spy at its office in Dublin, Ireland requiring him to preserve information on his mobile phone. "Deel's spy lied to the court-appointed solicitor about the location of his phone, and then locked himself in a bathroom -- seemingly in order to delete evidence from his phone -- all while the independent solicitor repeatedly warned him not to delete materials from his device and that his non-compliance was breaching a court order with penal endorsement," Rippling said in Monday's filing. "The spy responded: 'I'm willing to take that risk.' He then fled the premises." "We always prefer to win by building the best products and we don't turn to the legal system lightly," Parker Conrad, Rippling's co-founder and CEO, said in a Monday X post. "But we are taking this extraordinary step to send a clear message that this type of misconduct has no place in our industry."

Read more of this story at Slashdot.

Sending Kubernetes and AI into orbit as devices move from 'glorified sensors' to 'decision-making'

SUSECON 2025 Edge technology is finally past the tipping point thanks to inferencing and AI, according to SUSE CTO Brent Schroeder.…

SourceHut says it's getting DDoSed by LLM bots

SourceHut, an open source git-hosting service, says web crawlers for AI companies are slowing down services through their excessive demands for data.…

Don't laugh. This kind of warning shows crims are getting desperate

Dark web analysts at infosec software vendor Fortra have discovered an extortion crew named Ox Thief that threatened to contact Edward Snowden if a victim didn’t pay to protect its data – a warning that may be an indicator of tough times in the ransomware world for some, at least.…

A newly FDA-approved form of adaptive deep-brain stimulation (DBS) for Parkinson's disease adjusts electrical stimulation in real time based on an individual's brain signals, improving symptom control and reducing medication dependence. Scientific American: For decades, Keith Krehbiel took high doses of medications with a debilitating side effect -- severe nausea -- following his diagnosis with early-onset Parkinson's disease at age 42 in 1997. When each dose wore off, he experienced dyskinesia -- involuntary, repetitive muscle movements. In his case, this consisted of head bobbing and weaving. Krehbiel is among one million Americans who live with this progressive neurological disorder, which causes slowed movements, tremors and balance problems. But soon after surgery to implant electrodes into specific areas of his brain in 2020, his life dramatically improved. "My tremor went away almost entirely," says Krehbiel, now age 70 and a professor emeritus of political science at the Stanford Graduate School of Business, whose Parkinson's symptoms began at age 40 and were initially misdiagnosed as repetitive stress injury from computer use. "I reduced my Parkinson's meds by more than two thirds," he adds. "And I no longer have a sensation of a foggy brain, nor nausea or dyskinesia." Krehbiel was the first participant to enroll in a clinical trial testing a new form of deep-brain stimulation (DBS), a technology that gained approval from the U.S. Food and Drug Administration for Parkinson's tremor and essential tremor in 1997 (it was later approved for other symptoms and conditions). The new adaptive system adjusts stimulation levels automatically based on the person's individual brain signals. In late February it received FDA approval for Parkinson's disease "based on results of the international multicenter trial, which involved participants at 10 sites across a total of four countries -- the U.S., the Netherlands, Canada and France. This technology is suitable for anyone with Parkinson's, not just individuals in clinical trials, says Helen Bronte-Stewart, the recent trial's global lead investigator and a neurologist specializing in movement disorders at Stanford Medicine. "Like a cardiac pacemaker that responds to the rhythms of the heart, adaptive deep-brain stimulation uses a person's individual brain signals to control the electric pulses it delivers," Bronte-Stewart says. "This makes it more personalized, precise and efficient than older DBS methods." "Traditional DBS delivers constant stimulation, which doesn't always match the fluctuating symptoms of Parkinson's disease," adds neurologist Todd Herrington, another of the trial's investigators and director of the deep-brain stimulation program at Massachusetts General Hospital. With adaptive DBS, "the goal is to adjust stimulation in real time to provide more effective symptom control, fewer side effects and improved patient quality of life." Current FDA approval of this adaptive system is for the treatment of Parkinson's only, not essential tremor, dystonia (a neurological disorder that causes excessive, repetitive and involuntary muscle contractions) or epilepsy, which still rely on traditional, continuous DBS, Herrington says.

Read more of this story at Slashdot.